Founded in 2005 by Myrtle Potter, Myrtle Potter & Company specializes in devising novel strategies to maximize the value of prescription drug brands and portfolios.
"We have a history of working with pharmaceutical and biotech companies to maximize the commercial value of their innovative products," said Myrtle Potter, CEO.
"We are eager to couple Esperion’s lipid-regulating drug development expertise with our commercialization expertise as we work together to successfully commercialize the ETC-1002 portfolio."
Myrtle Potter & Company, founded in 2005, is a life science and healthcare advisory firm. Expertise includes business strategy, product commercialization, customer engagement, product development, business development, loss of exclusivity strategies and organization development.
With more than 30 years in the healthcare industry, Potter has built an advisory firm that brings proven and relevant experience to their clients.